A positive laboratory inhibition result can justify a clinical interaction study. The clinical study then answers a more specific question about the exposure actually tested. A 2017 tenapanor paper followed that sequence using midazolam as a CYP3A probe.
Tenapanor inhibited CYP3A4/5 in human liver microsomes, with reported half-maximal inhibitory concentrations of approximately 0.4–0.7 micromolar. Researchers subsequently compared oral midazolam alone with midazolam administered after repeated tenapanor dosing in healthy volunteers.
Participants received tenapanor 15 mg twice daily for 14 days before the second midazolam administration. The midazolam area-under-the-curve ratio was 107%, with a 90% confidence interval of 101–113%. The peak-concentration ratio was 104%, with a 90% confidence interval of 89.6–122%. These ratios compare the combination condition with midazolam alone.
The paper confirmed minimal systemic availability of tenapanor. Access of an inhibitor to the relevant enzyme is important when translating a microsomal finding to a clinical setting. The observed human results showed only a small net change in midazolam exposure under the tested regimen.
The clinical experiment used healthy volunteers and a fixed treatment sequence. Its directly observed evidence concerns the tested dose, duration, probe, and population. The authors discussed extrapolation to a higher tenapanor dose, but that projection remained separate from the measured comparison.
For forensic interpretation, an interaction opinion benefits from separating enzyme-screening evidence, measured human pharmacokinetics, and extrapolation to the patient’s circumstances. Each step supports a different degree of certainty.